Schellenberg Wittmer advised Boehringer Ingelheim, one of the largest pharmaceutical companies, on the acquisition of Evax AG. Evax AG is a Swiss biotech company focused on equine health.
The Schellenberg Wittmer team consisted of Pascal Hubli (overall lead), Florian Angstmann, Olivia Wipf, Filip Majernik, Nanina Lätsch and Caroline Genz (all Corporate / M&A), Philipp Groz and Alisa Zehner (both IP / Life Sciences), Petra Spring and Rachel Pawlik (both Employment), Roland Mathys and Jacqueline Brunner (both ICT / Data Protection) as well as Josef Caleff and Klaudia Bibaj (both Real Estate).